Abstract: Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.
Type:
Grant
Filed:
September 20, 1989
Date of Patent:
June 17, 1997
Assignee:
Praxis Biologics, Inc.
Inventors:
Peter R. Paradiso, Stephen W. Hildreth, Branda T. Hu, Antonia Martin-Gallardo, Rasappa Arumugham, Edward E. Walsh
Abstract: Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.
Type:
Grant
Filed:
September 20, 1988
Date of Patent:
June 29, 1993
Assignee:
Praxis Biologics, Inc.
Inventors:
Peter R. Paradiso, Stephen W. Hildreth, Branda T. Hu, Antonia Martin-Gallardo, Rasappa Arumugham
Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.
Type:
Grant
Filed:
February 15, 1990
Date of Patent:
March 23, 1993
Assignee:
Praxis Biologics, Inc.
Inventors:
Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization.
Type:
Grant
Filed:
November 9, 1989
Date of Patent:
May 5, 1992
Assignee:
Praxis Biologics, Inc.
Inventors:
Robert A. Deich, Gary Zlotnick, Bruce Green
Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods includng novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequence encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization.
Type:
Grant
Filed:
November 9, 1989
Date of Patent:
April 28, 1992
Assignee:
Praxis Biologics, Inc.
Inventors:
Robert A. Deich, Gary W. Zlotnick, Bruce A. Green